Vaxcyte, Inc.
PCVX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 2.62 | -1.24 | -0.14 | 0.35 |
| FCF Yield | -4.76% | -5.98% | -5.67% | -10.36% |
| EV / EBITDA | -21.58 | -12.33 | -10.71 | -12.04 |
| Quality | ||||
| ROIC | -16.87% | -36.86% | -25.48% | -33.86% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.98 | 0.74 | 0.76 | 1.21 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -30.27% | -106.67% | -37.90% | -167.77% |
| Safety | ||||
| Net Debt / EBITDA | 0.71 | 0.79 | 3.81 | 0.53 |
| Interest Coverage | 0.00 | 0.00 | -116,128.00 | -14,810.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -9.20 | -1.50 |
| Cash Conversion Cycle | -1,116.12 | -70.99 | -428.47 | -1,613.71 |